Meniscus Regeneration by Endogenous Stem/Progenitor Cells

内源干/祖细胞的半月板再生

基本信息

  • 批准号:
    8697945
  • 负责人:
  • 金额:
    $ 101.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-05-01 至 2019-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The meniscus is a semi-lunar and wedge-shaped fibrocartilaginous structure between the distal femoral condyle and the proximal tibial plateaus in the knee joint. Meniscus plays indispensable roles in joint congruence, shock absorption, and stress transmission. Meniscus injuries do not heal spontaneously. Clinically, over one million patients undergo meniscectomy each year in the United States. Allograft transplantation from cadavers is the primary clinical substitute of resected meniscus, but suffers from donor shortage, pathogen transmission, immunorejection and tissue mis-match. Meniscectomy, with or without allograft transplantation, alleviates pain at best, but significantly increases the incidence of osteoarthritis later in life. By 2020, a total of 67 million Americans will suffer fro arthritis. Not surprisingly, regeneration of knee meniscus is an aspiring goal in orthopedic medicine, but has encountered multiple barriers. No regenerative therapies exist for meniscus injuries at this time. One of the critical barriers of meniscus regeneration is our insufficient knowledge of meniscus cells, known as fibrochondrocytes whose origin and lineage derivation are poorly understood. Our preliminary data demonstrate that 1) fibrochondrocytes were derived from adult stem/progenitor cells by step-wise induction with two recombinant human growth factors that are both necessary and sufficient for induction of fibrochondrocytes in vitro and in vivo; 2) spatiotemporal release of these two growth factors induced de novo formation of multiphase fibrocartilage tissues in anatomically correct bioscaffolds that replaced partially resected knee meniscus in vivo in a preclinical model. Host endogenous cells were recruited into anatomically correct, microporous scaffolds and produced primarily type I collagen in the outer region, type II collagen in the inner region and blended type I and II collagens in the intermediate zone of the regenerated meniscus tissues. The overall objectives of this proposal are to optimize strategies for the recruitment of host endogenous cells and differentiation into fibrochondrocytes in our existing pre-clinical model of meniscus regeneration, without cell transplantation. Our overarching hypothesis is that spatiotemporal delivery of specific bioactive cues regulates the recruitment and fibrochondrogenic differentiation of endogenous cells, including stem/progenitor cells, towards meniscus regeneration. No regenerative therapies exist for fibrocartilage defects in intervertebral disks, tendon-bone junction and the temporomandibular joint. The planned studies will identify fibrochondrocyte populations that are pivotal for meniscus regeneration, and may have implications for the regeneration of other fibrocartilage structures. The planned cell recruitment strategies may be applicable in the regeneration of other tissues.
描述(申请人提供):半月板是位于股骨远端髁和胫骨近端平台之间的半月形楔形纤维软骨结构

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LISA A FORTIER其他文献

LISA A FORTIER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LISA A FORTIER', 18)}}的其他基金

Mitoprotective therapy for treatment of ankle PTOA
线粒体保护疗法治疗踝关节 PTOA
  • 批准号:
    9445145
  • 财政年份:
    2017
  • 资助金额:
    $ 101.24万
  • 项目类别:
Mitoprotective therapy for treatment of ankle PTOA
线粒体保护疗法治疗踝关节 PTOA
  • 批准号:
    9754782
  • 财政年份:
    2017
  • 资助金额:
    $ 101.24万
  • 项目类别:
Meniscus Regeneration by Endogenous Stem/Progenitor Cells
内源干/祖细胞的半月板再生
  • 批准号:
    9283228
  • 财政年份:
    2014
  • 资助金额:
    $ 101.24万
  • 项目类别:
Meniscus Regeneration by Endogenous Stem/Progenitor Cells
内源干/祖细胞的半月板再生
  • 批准号:
    8838048
  • 财政年份:
    2014
  • 资助金额:
    $ 101.24万
  • 项目类别:
Meniscus Regeneration by Endogenous Stem/Progenitor Cells
内源干/祖细胞的半月板再生
  • 批准号:
    9145633
  • 财政年份:
    2014
  • 资助金额:
    $ 101.24万
  • 项目类别:
GTPase Activating Proteins in Aging and Osteoarthritis
衰老和骨关节炎中的 GTP 酶激活蛋白
  • 批准号:
    7230219
  • 财政年份:
    2006
  • 资助金额:
    $ 101.24万
  • 项目类别:
GTPase Activating Proteins in Aging and Osteoarthritis
衰老和骨关节炎中的 GTP 酶激活蛋白
  • 批准号:
    7096245
  • 财政年份:
    2006
  • 资助金额:
    $ 101.24万
  • 项目类别:
ROLE OF RHO PROTEINS IN CHONDROCYTE DIFFERENTIATION
RHO 蛋白在软骨细胞分化中的作用
  • 批准号:
    6349717
  • 财政年份:
    2000
  • 资助金额:
    $ 101.24万
  • 项目类别:
ROLE OF RHO PROTEINS IN CHONDROCYTE DIFFERENTIATION
RHO 蛋白在软骨细胞分化中的作用
  • 批准号:
    6627909
  • 财政年份:
    2000
  • 资助金额:
    $ 101.24万
  • 项目类别:
ROLE OF RHO PROTEINS IN CHONDROCYTE DIFFERENTIATION
RHO 蛋白在软骨细胞分化中的作用
  • 批准号:
    6497165
  • 财政年份:
    2000
  • 资助金额:
    $ 101.24万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 101.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 101.24万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 101.24万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 101.24万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 101.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 101.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 101.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 101.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 101.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 101.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了